Upon 7 days of treatment with 0.5–2 μM CSF1Ri± anti-CD40 mAb we observed a non-significant trend of reduced macrophage viability and a significant decrease in tumor cell viability with 0.5–2 μM CSF1Ri ± anti-CD40 mAb treatment conditions (Figures 4B, D) (p < 0.05). This evidence concerns the gene CD40 and neoplasm.